Effect of lansoprazole and rabeprazole on tacrolimus pharmacokinetics in healthy volunteers with CYP2C19 mutations

Journal of Pharmacy and Pharmacology

Volumn 56, Issue 8, 2004, Pages 1055-1059

  Itagaki, Fumio ^a   Homma, Masato ^a   Yuzawa, Kenji ^a   Nishimura, Masuhiro ^b   Naito, Shinsaku ^b   Ueda, Nobuhiko ^b   Ohkohchi, Nobuhiro ^a   Kohda, Yukinao ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

^b OTSUKA PHARMACEUTICAL CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2C19; LANSOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE; TACROLIMUS;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG MECHANISM; FEMALE; GENE MUTATION; GENOTYPE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; OPEN STUDY; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; STATISTICAL SIGNIFICANCE; VOLUNTEER;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADMINISTRATION, ORAL; ADULT; ANTI-ULCER AGENTS; AREA UNDER CURVE; ARYL HYDROCARBON HYDROXYLASES; BENZIMIDAZOLES; CROSS-OVER STUDIES; DRUG INTERACTIONS; FEMALE; GENOTYPE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; OMEPRAZOLE; TACROLIMUS;

EID: 4344692334     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1211/0022357043914     Document Type: Article

References (19)

1. Adachi, K., Katsube, T., Kawamura, A., Takashima, T., Yuki, M, Amano K., Ishihara, S., Fukuda, R., Watanabe, M., Kinoshita, Y. (2000) CYP2C19 genotype status and intragastric pH during dosing with lansoprazole or rabeprazole. Aliment. Pharmacol. Ther. 14: 1259-1266
2. Christians, U., Jacobsen, W., Benet, L. Z., Lampen, A. (2002) Mechanisms of clinically relevant drug interactions associated with tacrolimus. Clin. Pharmacokinet. 41: 813-851
3. Edeki, T. I., Goldstein, J. A., de Morais, S. M. F., Hajiloo, L., Butler, M., Chapdelaine, P., Wilkinson, G. R. (1996) Genetic polymorphism of S-mephenytoin 4′-hydroxylation in African Americans. Pharmacogenetics 6: 357-360
4. Furuta, T., Ohashi, K., Kobayashi, K., Iida, I., Yoshida, H., Shirai, N., Takashima, M., Kosuge, K., Hanai, H., Chiba, K., Ishizaki, T., Kaneko, E. (1999) Effects of clarithromycin on the metabolism of omeprazole in relation to CYP2C19 genotype status in humans. Clin. Pharmacol. Ther. 66: 265-274
5. Furuta, T., Shirai, N., Xiao, F., Ohashi, K., Ishizaki, T. (2001) Effect of high-dose lansoprazole on intragastric pH in subjects who are homozygous extensive metabolizers of cytochrome P4502C19. Clin. Pharmacol. Ther. 70: 484-492
6. Hashida, T., Masuda, S., Uemoto, S., Saito, H., Tanaka, K., Inui, K. (2001) Pharmacokinetic and prognostic significance of intestinal MDR1 expression in recipients of living-donor liver transplantation. Clin. Pharmacol. Ther. 69: 308-316
7. Homma, M., Itagaki, F., Yuzawa, K., Fukao, K., Kohda, Y. (2002) Effects of lansoprazole and rabeprazole on tacrolimus blood concentration: case of a renal transplant recipient with CYP2C19 gene mutation. Transplantation 73: 303-304
8. Ieiri, I., Kisimoto, Y., Okochi, H., Momiyama, K., Morita, T., Kitano, M., Morisawa, T., Fukushima, Y., Nakagawa, K., Hasegawa, J., Otsubo, K., Ishizaki, T. (2001) Comparison of the kinetic disposition of and serum gastrin change by lansoprazole versus rabeprazole during an 8-day dosing scheme in relation to CYP2C19 polymorphism. Eur. J. Clin. Pharmacol. 57: 485-492
9. Ishizaki, T., Horai, Y. (1999) Cytochrome P450 and the metabolism of proton pump inhibitors: emphasis on rabeprazole. Aliment. Pharmacol. Ther. 13: 27-36
10. Itagaki, F., Homma, M., Yuzawa, K., Fukao, K., Kohda, Y. (2002) Drug interaction of tacrolimus and proton pump inhibitors in renal transplant recipients with CYP2C19 gene mutation. Transplant. Proc. 34: 2777-2778
11. Karol, M. D., Granneman, G. R., Alexander, K. (1995) Determination of lansoprazole and five metabolites in plasma by high-performance liquid chromatography. J. Chromatogr. B 668: 182-186
12. Katsuki, H., Nakamura, C., Arimori, K., Fujiyama, S., Nakano, M. (1997) Genetic polymorphism of CYP2C19 and lansoprazole pharmacokinetics in Japanese subjects. Eur. J. Clin. Pharmacol. 52: 391-396
13. Kosuge, K., Jun, Y., Watanabe, H., Kimura, M., Nishimoto, M., Ishizaki, T., Ohashi, K. (2001) Effects of CYP3A4 inhibition by diltiazem on pharmacokinetics and dynamics of diazepam in relation to CYP2C19 genotype status. Drug. Metab. Dispos. 29: 1284-1289
14. Logan, A. J., Morris-Sriff, G. J., Bowrey, D. J., Jurewicz, W. A. (2002) Upper gastrointestinal complications after renal transplantation. Clin. Transplant. 16: 163-167
15. Lorf, T., Ramadori, G., Ringe, B., Schwörer, H. (2000) The effect of pantoprazole on tacrolimus and cyclosporin. A blood concentration in transplant patients. Eur. J. Clin. Pharmacol. 56: 439-440
16. de Morais, S. M. F., Wilkinson, G. R., Blaisdell, J., Nakamura, K., Meyer, U. A., Goldstein, J. A. (1994) The major genetic defect responsible for the polymorphism, of S-mephenytoin metabolism in humans. J. Biol. Chem. 269: 15 419-15 422
17. Pauli-Magnus, C., Rekersbrink, S., Klotz, U., Fromm, M. F. (2001) Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein. Naunyn Schmiedebergs Arch. Pharmacol. 364: 551-557
18. Plosker, G. L., Foster, R. H. (2000) Tacrolimus: a further update of its pharmacology and therapeutic use in the management of organ transplantation. Drugs 59: 323-389
19. Saeki, T., Ueda, K., Tanigawara, Y., Hori, R., Komano, T. (1993) Human P-glycoprotein transports cyclosporin A and FK506. J. Biol. Chem. 268: 6077-6080